OKUR Insider Trading
Insider Ownership Percentage: 2.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $3,418,078.56
OnKure Therapeutics Share Price & Price History
Current Price: $3.00
Price Change: ▼ Price Decrease of -0.01 (-0.33%)
As of 01/16/2026 05:00 PM ET
OnKure Therapeutics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/22/2025 | Jason A Leverone | CFO | Sell | 302 | $2.97 | $896.94 | 16,301 | |
| 12/22/2025 | Nicholas A Saccomano | CEO | Sell | 87 | $2.97 | $258.39 | 7,419 | |
| 9/22/2025 | Jason A Leverone | CFO | Sell | 303 | $2.62 | $793.86 | 12,603 | |
| 9/22/2025 | Nicholas A Saccomano | CEO | Sell | 88 | $2.62 | $230.56 | 3,506 | |
| 6/23/2025 | Jason A Leverone | CFO | Sell | 303 | $2.38 | $721.14 | 12,906 | |
| 6/23/2025 | Nicholas A Saccomano | CEO | Sell | 88 | $2.38 | $209.44 | 3,594 | |
| 5/15/2025 | Cormorant Asset Management, Lp | Major Shareholder | Sell | 1,813,439 | $1.85 | $3,354,862.15 | | |
| 5/12/2025 | Cormorant Asset Management, Lp | Major Shareholder | Sell | 24,300 | $1.99 | $48,357.00 | 1,813,439 | |
| 4/7/2025 | Jason A Leverone | CFO | Sell | 1,844 | $2.67 | $4,923.48 | 13,209 | |
| 4/7/2025 | Nicholas A Saccomano | CEO | Sell | 516 | $2.67 | $1,377.72 | 3,682 | |
| 4/4/2025 | Jason A Leverone | CFO | Sell | 1,278 | $3.33 | $4,255.74 | 15,053 | |
| 4/4/2025 | Nicholas A Saccomano | CEO | Sell | 358 | $3.33 | $1,192.14 | 4,198 | |
OnKure Therapeutics Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 12/1/2025 | Cantor Fitzgerald L. P. | 491,863 | $1.35M | 0.0% | -26.5% | 3.630% |  |
| 11/17/2025 | Citadel Advisors LLC | 1,016,613 | $2.80M | 0.0% | -6.7% | 7.503% |  |
| 11/17/2025 | Cantor Fitzgerald L. P. | 491,863 | $1.35M | 0.0% | -26.5% | 3.630% |  |
| 11/14/2025 | Shay Capital LLC | 917,934 | $2.52M | 0.2% | +17.4% | 6.784% |  |
| 11/14/2025 | Bridgeway Capital Management LLC | 19,500 | $54K | 0.0% | -22.0% | 0.144% |  |
| 11/14/2025 | Prosight Management LP | 267,959 | $0.74M | 0.2% | +67.8% | 1.980% |  |
| 11/10/2025 | Highbridge Capital Management LLC | 650,218 | $1.79M | 0.1% | -2.0% | 4.806% |  |
| 11/7/2025 | GSA Capital Partners LLP | 59,224 | $0.16M | 0.0% | +172.1% | 0.438% |  |
| 11/7/2025 | Vanguard Group Inc. | 678,226 | $1.87M | 0.0% | -4.0% | 5.013% |  |
| 8/15/2025 | Shay Capital LLC | 782,046 | $1.87M | 0.2% | +417.8% | 5.789% |  |
| 8/15/2025 | Rangeley Capital LLC | 29,902 | $71K | 0.1% | N/A | 0.221% |  |
| 8/15/2025 | Acorn Capital Advisors LLC | 2,839,674 | $6.79M | 4.4% | +97.2% | 21.019% |  |
| 8/13/2025 | Affinity Asset Advisors LLC | 347,990 | $0.83M | 0.1% | -11.7% | 2.576% |  |
| 8/12/2025 | XTX Topco Ltd | 10,643 | $25K | 0.0% | N/A | 0.079% |  |
| 8/12/2025 | Highbridge Capital Management LLC | 663,607 | $1.59M | 0.1% | +51.2% | 4.912% |  |
| 8/8/2025 | Bailard Inc. | 14,239 | $34K | 0.0% | N/A | 0.105% |  |
| 5/16/2025 | ADAR1 Capital Management LLC | 10,000 | $43K | 0.0% | N/A | 0.074% |  |
| 5/14/2025 | Affinity Asset Advisors LLC | 394,159 | $1.70M | 0.2% | +173.4% | 2.934% |  |
| 2/17/2025 | Vestal Point Capital LP | 635,000 | $5.46M | 0.3% | N/A | 19.012% |  |
| 2/17/2025 | Two Sigma Advisers LP | 14,228 | $0.12M | 0.0% | N/A | 0.426% |  |
| 2/17/2025 | Tang Capital Management LLC | 294,626 | $2.53M | 0.2% | N/A | 8.821% |  |
| 2/17/2025 | Shay Capital LLC | 15,016 | $0.13M | 0.0% | N/A | 0.450% |  |
| 2/17/2025 | Sphera Funds Management LTD. | 87,354 | $0.75M | 0.1% | N/A | 2.615% |  |
| 2/17/2025 | Prosight Management LP | 63,754 | $0.55M | 0.2% | N/A | 1.909% |  |
| 2/17/2025 | OMERS ADMINISTRATION Corp | 12,100 | $0.10M | 0.0% | N/A | 0.362% |  |
| 2/17/2025 | NEA Management Company LLC | 478,548 | $4.12M | 0.2% | N/A | 14.328% |  |
| 2/17/2025 | Millennium Management LLC | 144,099 | $1.24M | 0.0% | N/A | 4.314% |  |
| 2/17/2025 | Deep Track Capital LP | 523,989 | $4.51M | 0.2% | N/A | 15.688% |  |
| 2/17/2025 | Cubist Systematic Strategies LLC | 20,549 | $0.18M | 0.0% | N/A | 0.615% |  |
| 2/17/2025 | Cantor Fitzgerald L. P. | 35,700 | $0.29M | 0.0% | N/A | 1.069% |  |
| 2/17/2025 | Citadel Advisors LLC | 1,074,314 | $8.78M | 0.0% | N/A | 32.165% |  |
| 2/17/2025 | Bank of America Corp DE | 249,642 | $2.15M | 0.0% | N/A | 7.474% |  |
| 2/17/2025 | 683 Capital Management LLC | 43,371 | $0.37M | 0.0% | N/A | 1.299% |  |
| 2/17/2025 | Acorn Capital Advisors LLC | 1,439,674 | $12.38M | 6.8% | N/A | 43.104% |  |
| 2/14/2025 | Samsara BioCapital LLC | 824,155 | $7.09M | 1.0% | N/A | 24.675% |  |
| 2/14/2025 | Nantahala Capital Management LLC | 54,777 | $0.47M | 0.0% | N/A | 1.640% |  |
| 2/14/2025 | Northern Trust Corp | 19,177 | $0.17M | 0.0% | N/A | 0.574% |  |
| 2/14/2025 | Boothbay Fund Management LLC | 78,021 | $0.67M | 0.0% | N/A | 2.336% |  |
| 2/14/2025 | Altium Capital Management LLC | 218,386 | $1.88M | 0.5% | N/A | 6.539% |  |
| 2/13/2025 | Affinity Asset Advisors LLC | 144,159 | $1.24M | 0.2% | N/A | 4.316% |  |
| 2/13/2025 | Carlyle Group Inc. | 269,895 | $2.33M | 0.5% | N/A | 8.081% |  |
| 2/13/2025 | Walleye Capital LLC | 13,495 | $0.12M | 0.0% | N/A | 0.404% |  |
| 2/13/2025 | XTX Topco Ltd | 18,633 | $0.16M | 0.0% | N/A | 0.558% |  |
| 2/13/2025 | Barclays PLC | 8,741 | $75K | 0.0% | N/A | 0.262% |  |
| 2/13/2025 | Renaissance Technologies LLC | 47,450 | $0.41M | 0.0% | N/A | 1.421% |  |
| 2/12/2025 | Aldebaran Capital LLC | 45,572 | $0.39M | 0.4% | N/A | 1.363% |  |
| 2/12/2025 | Aisling Capital Management LP | 88,607 | $0.76M | 0.3% | N/A | 2.651% |  |
| 2/12/2025 | Geode Capital Management LLC | 76,599 | $0.66M | 0.0% | N/A | 2.291% |  |
| 2/12/2025 | Highbridge Capital Management LLC | 399,743 | $3.44M | 0.1% | N/A | 11.958% |  |
Data available starting January 2016
OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.
Read More on OnKure Therapeutics
Volume
24,521 shs
Average Volume
83,948 shs
Market Capitalization
$40.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.47
Who are the company insiders with the largest holdings of OnKure Therapeutics?